Table 3.

Subgroup analysis

Treatment	ICU admission n =19	No ICU admission n =32	P value
LVEF % (median/IQR)	59.0 (55.5–60.0)	58.5 (54.4–60.0)	0.56
GLS % (median/IQR)	−19.7 (−21– −19.1)	−17.7 (−18.5– −16.4)	0.005
TAPSE mm (median/IQR)	24.0 (18.5–27.0)	22.0 (20.0–26.0)	0.3
RV S’ cm/sec (median/IQR)	15.0 (12.2–18.8)	14.0 (11.0–15.0)	0.1
Troponin T > 14 ng/l	n = 15 (79%)	n = 9 (28%)	0.005*
NT-proBNP >300 pg/ml	n = 4 (21%)	n = 20 (63%)	0.01*
Complication	Pulmonary embolism n =9	No pulmonary embolism n =42	P value
TAPSE mm (median/IQR)	27 (25–28)	21 (19–25.8)	0.008
RV S’ cm/sec (median/IQR)	16 (14–20)	14 (12–15)	0.026
Troponin T > 14 ng/l	n = 6 (67%)	n = 18 (43%)	0.46*
NT-proBNP >300 pg/ml	n = 3 (33%)	n = 21 (50%)	0.46*
Troponin T	≤14 ng/l n =23	>14 ng/l n =24	P value
LVEF % (median/IQR)	57 (53–60)	59 (56–60)	0.15
GLS % (median/IQR)	−18.1 (−18.7– −16.7)	−19.2 (−20– −17.1)	0.20
TAPSE mm (median/IQR)	22 (19–25.5)	22.5 (20–27)	0.44
RV S’ cm/sec (median/IQR)	12 (11–14)	15 (14–18.5)	0.004
NT-proBNP	≤300 pg/ml n =24	>300 pg/ml n =24	P value
LVEF % (median/IQR)	60 (57–60)	59 (54–60)	0.62
GLS % (median/IQR)	−18.8 (−19– −17.5)	−18 (−19.4– −16.5)	0.53
TAPSE mm (median/IQR)	24.5 (19–27)	21.5 (20–26.3)	0.97
RV S’ cm/sec (median/IQR)	14 (12–16.5)	14 (11.5–16.5)	0.8

All values were tested with a Mann-Whitney U test, except for (*) which was done with a Fisher’s exact test

GLS global longitudinal strain, LV left ventricular, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-B-type natriuretic peptide, RV S’ right ventricular systolic excursion velocity, TAPSE tricuspid annular plane systolic excursion